



Abstract Type : Oral presentation

Abstract Submission No.: A-0602

Abstract Topic : Non-dialysis CKD

Efficacy and Safety of Tivozanib in treating Advanced Renal Cell carcinoma : A Systematic Review and Single Arm Meta-analysis

Abimanyu Sakh, Ryan C. Harliman

Department of Medical Student, Faculty of Medicine, Pelita Harapan University, Indonesia


Objectives : This systematic review and single arm meta-analysis aim to analyse the efficacy and treatment-related adverse effects of tivozanib in treating Advanced Renal Cell carcinoma.

Methods : Systematic search was conducted by 2 authors that utilized several Database such as PubMed, Embase, Cochrane and Science Direct that had a maximum 10 years of publication time. Eligible studies are included in the inclusion criteria, some of it were (1) studies that got advanced renal carcinoma patient treated with Tivozanib, (2) a randomized controlled trial studies, (3) and studies that provide information of PFS, OS, that followed a RECIST 1.1 criteria results. Data were shown by forest plot and funnel plot for publication bias. Critical appraisal were conducted using Cochrane Risk of Bias 2 (RoB2).

Results : Four literature studies were included in this paper, with total of 768 patients. Efficacy were observed following the RECIST 1.1 criteria with a results of 1% CR (0.01 [0.01; 0.02]), 22% of PR (0.22 [0.16; 0.29]), 6% of PD (0.06 [0.01; 0.29]), and 25% of SD (0.25 [0.03; 0.80]). Treatment Related Adverse Effect is listed with Hypertension was the number one leading effect. This paper showed a great PFS and increase OS respectively.

Conclusions : This systematic review and single arm meta analysis provide a new approach treatment for Advanced Renal Cell Carcinoma patients, focusing on the tumor response and treatment related adverse effect. But due to the lack of publication, future research still needs to be conducted.

PRKSN_FOREST PLOT BARU.png



PRKSN_FOREST PLOT BARU.png

